April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Uveal Melanoma Patients With Increased Percentages of CD11b+ CD15+ Myeloid Derived Suppressor Cells in Blood Demonstrate Impaired T Cell Function
Author Affiliations & Notes
  • K. C. McKenna
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • K. M. Beatty
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • A. D. Singh
    Cole Eye Institute, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  K.C. McKenna, None; K.M. Beatty, None; A.D. Singh, None.
  • Footnotes
    Support  The Eye and Ear Foundation of Pittsburgh, RO1CA136776
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 843. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. C. McKenna, K. M. Beatty, A. D. Singh; Uveal Melanoma Patients With Increased Percentages of CD11b+ CD15+ Myeloid Derived Suppressor Cells in Blood Demonstrate Impaired T Cell Function. Invest. Ophthalmol. Vis. Sci. 2010;51(13):843.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine whether expansion of CD11b+ CD15+ myeloid derived suppressor cells (MDSC) in the blood of uveal melanoma (UM) patients was associated with impaired T cell function

Methods: : Blood was collected in CPT tubes with heparin (Becton Dickinson) from patients with a clinical diagnosis of UM (9 female, 9 male, aged 42-89) before surgery and in follow-up visits, and from healthy control donors (28 female, 26 male, aged 50-69). PBMC were isolated by centrifugation within 3 hours and then stored at room temperature in autologous plasma for 1-4 days. Flow cytometry was performed to evaluate expression of CD68 and CD15 on CD11b+ cells. CD11b+ cells were isolated from PBMC by magnetic cell separation and then PBMC with and without CD11b+ cells were labeled with CFSE and stimulated with PHA or anti-CD3/CD2/CD28 beads. Four days later proliferation of PBMC was determined by flow cytometric analysis of CFSE dilution.

Results: : Four UM patients demonstrated increased percentages of CD11b+ cells in PBMC (72.2%, 48.8%, 49.6%, 46.3% of total PBMC) that were two standard deviation greater than observed in healthy control donors (mean+/- standard deviation = 30 +/- 7.8 % of total PBMC). The percentage of CD11b+ cells that coexpressed CD15 in these patients was also elevated (48.3%, 31.5%, 21.4%, 26.7% of total PBMC) in comparison to healthy controls (median 4.4%, range= 1.09 -24.4% of total PBMC). In one of these UM patients, the percentage of T cells that had proliferated following mitogen stimulation (22%) was reduced two-fold in comparison to an age matched healthy control donor (43%). In another patient T cell proliferation within PBMC increased when CD11b+ cells were removed.

Conclusions: : Activated CD11b+ CD15+ granulocytes increased in certain UM patients reproducing our previously published results (McKenna, K. C. et al. 2009. Invest. Ophthalmol. Vis. Sci. 50:4295). T cell function was impaired by these granulocytes suggesting that they are myeloid derived suppressor cells which may contribute to UM progression by inhibiting tumor-specific T cell responses.

Keywords: melanoma • immunomodulation/immunoregulation • tumors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.